RepliCel Life Sciences (PK) Stock Price - REPCF

0.1778
-0.0179 (-9.15%)
0.1778
Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
RepliCel Life Sciences Inc (PK) REPCF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.0179 -9.15% 0.1778 0.1775 0.193 0.1916 0.1957 16:20:08
Bid Price Ask Price Spread Spread % News
0.0837 0.30 0.2163 72.1% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
7 13,063 $ 0.179715 $ 2,348 12,017 0.1051 - 0.365
Last Trade Time Type Quantity Stock Price Currency
11:26:44 4,999 $ 0.1778 USD

RepliCel Life Sciences (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.03M 28.29M 14.66M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
6.34k $ - 0.00% - -

more financials information »

RepliCel Life Sciences (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical REPCF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.17090.19570.159360.184157213,4130.00694.04%
1 Month0.17240.200.130.177785410,6590.00543.13%
3 Months0.2490.29590.130.183329211,344-0.0712-28.59%
6 Months0.16530.3650.10510.216916716,4960.01257.56%
1 Year0.270.3650.10510.215811714,858-0.0922-34.15%
3 Years0.56540.61460.10510.30476615,348-0.3876-68.55%
5 Years0.27181.470.04550.387802717,668-0.094-34.58%

RepliCel Life Sciences (PK) Description

RepliCel Life Sciences Inc. is developing autologous cell therapies to treat conditions including chronic tendon injuries, pattern baldness and UV-damaged and aging skin. All products are based on RepliCel's innovative technology which utilizes cells isolated from a patient's healthy hair follicles. RepliCel has also developed a proprietary, next-generation dermal injection device (RCI) designed for highly controllable delivery of dermatological injections. in 2017, RepliCel completed three phase 1 clinical studies including RCH-01 for pattern baldness from Androgenetic Alopecia, RCT-01 for chronic Achilles tendinosis, and RCS-01 for aging and UV-damaged skin. All trials successfully met their primary endpoints and provided significantly positive clinical efficacy data on secondary endpoints. Shiseido Company has an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China, and South Korea. They recently completed a clinical study in Japan which may lead to the product's near-term market launch there. In late 2018, RepliCel signed a license and co-development deal for its skin, tendon and injector technologies with YOFOTO (China) Health for Greater China.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.